Glofitamab

Definition

A bispecific monoclonal antibody, with potential antineoplastic activity. Glofitamab contains two antigen-recognition sites: one for human CD3, a T cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, glofitamab binds to both T-cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B-cells.

Also known as Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody RO7082859, Columvi, GLOFITAMAB, Glofitamab-gxbm, RO 7082859, RO-7082859, RO7082859 — per NCIT

Also identified as

• ATC L01FX28 per RXNORM
• NCIT NCIT:C148486 per NCIT
• SCTID 1363208001 per RXNORM
• UNII 06P3KLK2J8 per RXNORM

Indications

Organ Effects

1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.